Surfactant replacement therapy in respiratory distress syndrome

Respiratory distress syndrome (RDS) is one of the most important causes of breathing difficulty in premature newborns. Immature lungs produce too little pulmonary surfactant, a substance that reduces surface tension inside the alveoli. Without enough surfactant, the alveoli become difficult to open and may collapse repeatedly during each breath.

Surfactant replacement therapy has changed neonatal care by addressing the underlying biochemical problem rather than treating oxygen deficiency alone. When it is combined with antenatal corticosteroids, appropriate respiratory support, temperature control, and careful monitoring, it can reduce the need for prolonged mechanical ventilation and lower the risk of air-leak complications.

The subject remains central to perinatal and neonatal medicine. The scientific discussions associated with the FAOPS 2020 congress site reflected the importance of collaborative research, clinical training, and regional approaches to caring for mothers and premature infants.

Why surfactant deficiency causes respiratory failure

Pulmonary surfactant is produced by type II alveolar cells. It contains phospholipids and specific proteins that lower the surface tension at the air-liquid interface of the alveoli. This allows the lungs to remain open at the end of expiration and reduces the work required to take the next breath.

In a premature infant, surfactant production may be insufficient because the lungs have not completed their structural and biochemical development. The resulting alveolar instability causes atelectasis, reduced lung compliance, ventilation-perfusion mismatch, and increasing oxygen requirements. Blood gases may show hypoxemia, carbon dioxide retention, or respiratory acidosis as the condition progresses.

The clinical picture typically includes tachypnea, grunting, nasal flaring, intercostal or sternal recession, and cyanosis. Chest radiography may demonstrate a diffuse reticulogranular pattern with air bronchograms, although modern practice increasingly combines clinical assessment with lung ultrasound and blood gas trends. Other causes, including transient tachypnea, pneumonia, pulmonary hypertension, pneumothorax, and congenital heart disease, must be considered.

Preparing for treatment before birth and after delivery

The prevention of severe RDS begins before delivery. Antenatal corticosteroids accelerate fetal lung maturation and reduce neonatal respiratory morbidity when preterm birth is anticipated. Magnesium sulfate may be considered for neuroprotection at very early gestational ages, while careful decisions about timing and mode of delivery help avoid additional compromise.

At birth, effective stabilization is essential. The newborn should be kept warm, positioned to maintain airway patency, and assessed for breathing and heart rate. A preterm infant who is breathing spontaneously often benefits from early continuous positive airway pressure (CPAP), which helps preserve functional residual capacity without immediately exposing the lungs to invasive ventilation.

Oxygen should be titrated with a blender and guided by pulse oximetry rather than administered at a fixed high concentration. Excess oxygen can contribute to oxidative injury and retinopathy of prematurity, while inadequate oxygenation can harm the brain and other organs. Delayed cord clamping, when clinically appropriate, may support circulatory transition and reduce some complications of prematurity.

Surfactant is generally considered when clinical signs of RDS persist despite non-invasive respiratory support and the oxygen requirement rises. Treatment thresholds vary with gestational age, local protocols, respiratory support, and the infant’s overall condition. A deteriorating infant should not be kept on CPAP simply to delay treatment.

Selecting a surfactant and an administration method

Available surfactants are derived from animal sources or produced as synthetic preparations. Animal-derived products commonly contain surfactant proteins that improve spreading and function within the alveoli. Poractant alfa, beractant, and calfactant are examples used in different health systems. Product concentration and recommended dosing differ, so clinicians must follow the specific formulation guidance.

The route of administration is as important as the medication itself. Traditional treatment uses endotracheal intubation followed by surfactant delivery, sometimes with a period of mechanical ventilation. The INSURE approach—intubation, surfactant administration, and rapid extubation to CPAP—can reduce ventilator exposure in selected infants.

Less invasive surfactant administration, often called LISA or minimally invasive surfactant therapy, delivers the drug through a thin catheter while the infant continues spontaneous breathing on CPAP. This technique may reduce invasive ventilation and its associated lung injury when performed by a trained team. It requires careful preparation, skilled airway management, and a plan for escalation if the infant becomes unstable.

Timing, dosing, and repeat treatment

The timing of replacement therapy should be based on the infant’s respiratory trajectory rather than a single measurement. Increasing oxygen needs, worsening retractions, rising carbon dioxide, recurrent apnea, or a need for higher CPAP pressure can indicate that endogenous surfactant is inadequate. Early rescue treatment is generally more beneficial than waiting for profound respiratory failure.

A standard dose is administered according to the product’s concentration and weight-based recommendations. Poractant alfa, for example, may be given at an initial dose that differs from later doses, while other products use different volumes and dosing schedules. Accurate weight measurement, warming and handling of the preparation, and gentle mixing are important for consistent delivery.

Some infants need a second dose because the first dose was insufficient, was not distributed effectively, or was inactivated by inflammation, blood, protein leakage, or infection. Repeat administration should follow reassessment rather than an automatic schedule. Persistent oxygen need after treatment may reflect pneumonia, pulmonary hypertension, a patent ductus arteriosus, air leak, inadequate lung recruitment, or an incorrect diagnosis.

Surfactant should be delivered with close attention to airway position and cardiopulmonary status. Transient coughing, desaturation, bradycardia, changes in chest movement, or reflux of medication can occur during administration. Pausing briefly, adjusting ventilation, and confirming the airway can be necessary. A rapid improvement in compliance may require prompt reduction of ventilator pressure to prevent volutrauma.

Monitoring the response and preventing complications

The expected response includes improved oxygenation, better chest expansion, lower work of breathing, and improved lung compliance. These changes may occur within minutes, especially after an effective dose. Ventilator settings should be reassessed promptly because unchanged pressures after lung recruitment can deliver excessive tidal volumes.

Continuous pulse oximetry, heart rate monitoring, respiratory assessment, and serial blood gases help guide care. Lung ultrasound is increasingly useful for identifying patterns consistent with surfactant deficiency and for assessing treatment response without repeated radiation exposure. Chest radiography remains valuable when the diagnosis is uncertain or complications are suspected.

The main risks relate to airway manipulation and rapid changes in pulmonary mechanics. Hypoxemia, bradycardia, endotracheal tube obstruction, pulmonary hemorrhage, pneumothorax, and accidental extubation are recognized concerns. A well-prepared team, appropriate monitoring, and a clear escalation plan reduce avoidable harm.

Long-term outcomes depend on gestational age, infection, inflammation, oxygen exposure, and the duration and intensity of ventilation. Surfactant therapy does not eliminate the risk of bronchopulmonary dysplasia, but it can reduce the severity of early respiratory failure when used within a lung-protective strategy.

Applying evidence across different neonatal settings

Clinical protocols should account for available equipment, staffing, transport distances, and the experience of the neonatal team. A sophisticated delivery method may be unsuitable if clinicians cannot provide reliable monitoring or emergency intubation. In such circumstances, a simpler protocol delivered consistently may be safer than an advanced technique used without adequate support.

Training should include neonatal airway management, non-invasive ventilation, surfactant preparation, dose calculation, and recognition of treatment failure. Simulation-based practice can improve coordination during the first minutes after birth, when hypothermia, delayed ventilation, and medication errors are most likely to occur.

Perinatal risk is also shaped by maternal health and the environment. Research discussed through air pollution and preterm birth illustrates how fetal growth, premature delivery, and neonatal respiratory vulnerability may be connected before a baby reaches the delivery room. Prevention therefore involves maternal care, environmental policy, timely referral, and neonatal treatment working together.

Practical priorities for clinical teams

• Anticipate RDS in very preterm infants and prepare respiratory support before delivery.
• Use antenatal corticosteroids when preterm birth is likely and no contraindication applies.
• Begin appropriate CPAP or other non-invasive support while avoiding excessive oxygen exposure.
• Treat worsening RDS promptly with a suitable surfactant and the least invasive feasible technique.
• Reassess lung compliance and reduce ventilator pressures after treatment takes effect.

Research directions and clinical decision-making

Research continues to examine the best threshold for surfactant administration, the relative benefits of LISA and other minimally invasive methods, and the role of lung ultrasound in personalized treatment. Investigators are also evaluating synthetic surfactants, aerosolized delivery, and formulations designed to resist inactivation during inflammation or infection.

Future protocols may combine gestational age, oxygen requirement, CPAP pressure, respiratory rate, blood gas results, and ultrasound findings into prediction models. Such tools could help distinguish infants likely to respond to early surfactant from those who need immediate intubation or investigation for another disorder.

The central principle is straightforward: support spontaneous breathing when possible, replace surfactant before respiratory failure becomes severe, and continually adjust treatment to the infant’s changing physiology. Decisions should be individualized, documented clearly, and reviewed by a multidisciplinary team that includes obstetric, neonatal, respiratory, and nursing professionals.

Surfactant replacement therapy is most effective as part of coordinated perinatal care rather than as an isolated medication. Neonatal units can strengthen outcomes by updating protocols, training staff in minimally invasive delivery, auditing oxygen and ventilation practices, and sharing regional data. Clinicians and researchers can use the FAOPS community and related perinatal resources to advance safer, more consistent care for infants at risk of respiratory distress syndrome.